Gold prices bounce off 3-week lows; demand likely longer term
SAN DIEGO—Ma Songjiang, President and Director at Gyre Therapeutics, Inc. (NASDAQ:GYRE), a $974 million market cap biotech company, recently sold a total of $40,776 worth of company stock. The sales, executed under a Rule 10b5-1 trading plan, occurred in multiple transactions on March 7 and March 10, 2025, with prices ranging from $10.13 to $13.03 per share. The stock currently trades at $11.35, down nearly 15% year-to-date.
The transactions involved a total of 4,000 shares, as disclosed in a Form 4 filing with the Securities and Exchange Commission. Following these sales, Ma retains indirect ownership of 2,839,260 shares through a family member. Despite recent price weakness, analysts maintain a Strong Buy rating with a $20 price target, according to InvestingPro data.
This activity is part of a pre-arranged trading plan established in September 2024, which allows insiders to set up a schedule for selling stocks to avoid any potential conflicts of interest. InvestingPro analysis reveals the company maintains strong liquidity with a 3.72 current ratio, though it currently trades at elevated valuation multiples. Subscribers can access 6 additional key insights about GYRE’s financial health and valuation metrics.
In other recent news, Gyre Therapeutics announced the appointment of Ping Zhang as the lead independent director of its Board of Directors. Zhang will also serve on the Nominating and Corporate Governance Committee, bringing a robust financial background to the role. Additionally, changes were reported at its subsidiary, Gyre Pharmaceuticals, with Songjiang Ma taking over as Chairman after Ying Luo stepped down to focus on his role at GNI Group Ltd. Gyre Pharmaceuticals is advancing its pipeline in China, including ongoing clinical trials for its drug F351 and the commercialization of ETUARY®, which generated $112.1 million in net sales in 2023. The company is also developing treatments for conditions such as COPD, PAH, and ALF/ACLF. These developments are part of Gyre Therapeutics’ strategy, informed by its experience in rodent model mechanistic studies and clinical studies related to liver fibrosis. Han Ying, CEO of Gyre Therapeutics, expressed enthusiasm for Zhang’s addition, citing the potential for a transformative year ahead. The information for this report is based on a press release from Gyre Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.